Last updated 2026-07-20
- Acquired by Immunome, Inc. for $50M, Mar 2024
- Raised $30M Series B led by Novartis, Apr 2019
- Raised $17M Series A led by aMoon Fund, Mar 2018
Total raised
$47.0M
Last: Undisclosed Round 2019-05
Stage
Acquired
Founded
2017
Headcount
35
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
Ayala Pharmaceuticals is a clinical-stage precision oncology company dedicated to developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, particularly in genetically defined patient populations. The company's product candidates, AL101 and AL102, are designed to target cancer by addressing the underlying key drivers of tumor growth, specifically the aberrant activation of the Notch pathway with gamma-secretase inhibitors (GSIs). Ayala aims to enable personalized therapy for cancer patients. The company was founded in November 2017 with an experienced global management team and a strong investor base. In 2017, the company entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for its gamma-secretase inhibitors.
Funding history · 6 rounds · $47.0M total
2023-09
Reverse Merger
Undisclosed
2020-04
Follow-on PO
Undisclosed
2019-04
B Round
$30.0M
★ NovartisaMoon FundShavit Capital FundIsrael Biotech FundSBI JI Innovation FundHarel Insurance & Finance
2018-03
A Round
$17.0M
★ aMoon Fund★ Israel Biotech Fund★ Harel Insurance & Finance
2017-11
Grant
Undisclosed
2017-11
Seed
Undisclosed
★ aMoon Fund★ Israel Biotech Fund★ Harel Insurance & Finance
Headcount over time
From 19 (2019-05) to 30 (2024-04) · +11 (+58%) · 8 points · source: Finder history + radar grounding
Q&A
- What is Ayala Pharmaceuticals' current status?
- Ayala Pharmaceuticals was acquired by Advaxis in January 2023.
- What is Ayala Pharmaceuticals' primary focus?
- Ayala Pharmaceuticals is a clinical-stage precision oncology company focused on developing and commercializing small molecule therapeutics for patients with rare and aggressive cancers, particularly in genetically defined populations.
- Which product candidates are being developed by Ayala Pharmaceuticals?
- Ayala Pharmaceuticals is developing AL101 and AL102, both designed to target cancer by addressing the aberrant activation of the Notch pathway with gamma-secretase inhibitors (GSIs).
- When was Ayala Pharmaceuticals founded?
- Ayala Pharmaceuticals was founded in January 2017.
- What was the total amount of funding raised by Ayala Pharmaceuticals?
- Ayala Pharmaceuticals raised a total of $102,000,000 in funding.
- Which companies invested in Ayala Pharmaceuticals' May 2019 funding round?
- In May 2019, Novartis and Shavit Capital Fund were among the investors in.
- What was a key licensing agreement for Ayala Pharmaceuticals in 2017?
- In 2017, Ayala Pharmaceuticals entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for its gamma-secretase inhibitors.
- What is the employee count for Ayala Pharmaceuticals?
- Ayala Pharmaceuticals has an employee count in the 11-50 range.
Team · 1
Roni Mamluk
Founder · Founder and CEO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
rare-diseasescancergenomicscell-therapydrug-discoveryoncologytherapeuticspharmaceuticalslife-sciencespatients
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | ayalapharma.com |
|---|---|
| linkedin.com/company/18445059 |
Identifiers & details
| Legal name | Ayala Pharmaceuticals, Inc. |
|---|---|
| Founded | 2017-11 |
| Employees (exact) | 35 |
| Offices | Wilmington |
| Status reason | Acquired by Advaxis on Jan, 2023 |
Acquisitions & public offerings
Acquired by Immunome, Inc. 2024-03 $50.0M
Radar intelligence
Patents
| EPO | 16 |
|---|
Web history (Wayback)
| Domain | ayalapharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 24 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515748697 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2017-11-29 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2022 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | אופנהיימר 4 רחובות |